The global coronary stents market was valued at USD 6.68 billion in 2024 and is projected to increase from USD 7.02 billion in 2025 to USD 10.66 billion by 2032, registering a CAGR of 6.2% during the forecast period. In 2024, North America held the largest share of the market, accounting for 33.08%.
The global coronary stents market is experiencing steady growth, driven by the rising prevalence of cardiovascular diseases and the increasing demand for minimally invasive treatment options. Technological advancements in stent design, including drug-eluting and bioresorbable variants, are further enhancing adoption across healthcare systems. North America currently holds a dominant position due to advanced healthcare infrastructure and high procedural volumes, while the Asia-Pacific region is emerging as a rapidly growing market supported by a large patient base and expanding healthcare access.
Learn more here:
https://www.fortunebusinessinsights.com/industry-reports/coronary-stents-market-100065
Market Segmentation
The coronary stents market is segmented by product type, material, mode of delivery, and end-user. Product types include bare-metal stents, drug-eluting stents, and bioresorbable stents. Materials used range from metallic alloys to polymer-based structures designed for biocompatibility. The market is also categorized by delivery methods, such as balloon-expandable and self-expanding stents. End-users primarily include hospitals, specialty cardiac centers, and ambulatory surgical centers.
List Of Key Coronary Stents Companies Profiled:
Medtronic (Ireland)
Boston Scientific Corporation (U.S.)
BIOTRONIK SE & Co. KG (Germany)
Terumo Corporation (Japan)
Abbott (U.S.)
Relisys Medical Devices Limited. (India)
Braun SE (Germany)
MicroPort Scientific Corporation (China)
Stentys S.A. (France)
Meril Life Sciences Pvt. Ltd. (India)
Market Growth Drivers
Market growth is driven by the rising prevalence of cardiovascular diseases and increasing adoption of minimally invasive surgical procedures. Advancements in stent design, including drug-eluting and bioresorbable stents, are improving patient outcomes and fueling demand. A growing elderly population, unhealthy lifestyles, and increasing risk factors such as diabetes and hypertension are further contributing to the rising need for coronary interventions. In addition, supportive government initiatives and improved healthcare access in emerging economies are boosting adoption.
Market Restraining Factors
The market faces challenges such as the high cost of advanced stent technologies, which limits accessibility in low-income regions. Risks associated with stent implantation, including restenosis, thrombosis, and other complications, act as barriers to wider adoption. Stringent regulatory approval processes and product recalls also restrict market expansion. Moreover, the availability of alternative treatment options, such as coronary artery bypass grafting (CABG), poses competitive pressure on stent utilization.
Regional Analysis
North America dominates the market due to advanced healthcare infrastructure, high adoption of innovative stent technologies, and a large patient base with cardiovascular diseases. Europe follows closely, supported by favorable reimbursement systems, increasing awareness, and strong presence of medical device companies. The Asia-Pacific region is expected to experience the fastest growth, driven by a large population, rising incidence of heart diseases, and expanding healthcare investments in countries such as China and India. Latin America shows steady demand, supported by improving healthcare systems and awareness programs, though affordability remains a barrier. The Middle East and Africa have comparatively lower adoption rates due to limited infrastructure, but government-led healthcare modernization is creating new growth opportunities.